

***Yersinia pestis* LcrV Protein, Recombinant from *Escherichia coli***

**Catalog No. NR-32875**

This reagent is the property of the U.S. Government.

**Product Description:** Recombinant LcrV protein (*Yersinia pestis*, strain KIM5) was expressed in *Escherichia coli* (*E. coli*) BL21 cells. The N-terminal deca-histidine tagged protein was purified by nickel affinity chromatography. Cleavage with Factor Xa resulted in a protein with one extra histidine at the amino terminus. The protein preparation was treated with Triton X-114 to reduce endotoxin contamination.

**Lot<sup>1</sup>: 70011457**

**Manufacturing Date: 23MAY2018**


TEST	SPECIFICATIONS	RESULTS
Appearance	Clear and colorless, no particulate matter	Clear and colorless, no particulate matter
Purity by SDS-PAGE densitometer scan	~ 37 kDa band represents > 95% of total staining intensity above background	~ 37 kDa band represents > 90% of total staining intensity above background (Figure 1)
Western Blot Analysis with Monoclonal Anti-Histidine Tag <sup>2</sup> Prior to Factor Xa treatment Final product	Reactive Non-reactive	Reactive (Figure 2) Non-reactive
Concentration and Content by Bradford Assay <sup>3</sup>	Report results	1.2 mg per mL (1.2 mg per vial)
Endotoxin Content (Limulus Amoebocyte Lysate Assay)	Report results	< 8.1 EU per mg
Filtration	Report	0.2 µm filtered

<sup>1</sup>NR-32875 was extracted from a preparation of *E. coli* BL21(DE3) cells and purified by nickel affinity and gel filtration chromatography. The N-terminal histidine tag was removed from the protein by digestion with Factor Xa (Novagen® Catalog No. 69036).

<sup>2</sup>Clone AD 1.1.10, R&D Systems® MAB050

<sup>3</sup>Using BSA as a standard

**Figure 1: SDS-PAGE**




Lane 1: SeeBlue™ Plus2 Protein standard

Lane 2: NR-32875, Final Product (1.0 µg)

Lane 3: NR-32875, Prior to Factor-Xa Treatment (1.0 µg)

Figure 2: Western Blot



Lane 1: MagicMark™ XP Protein Standard  
Lane 2: NR-32875, Final Product (1.0 µg)  
Lane 3: NR-32875, Prior to Factor-Xa Treatment (1.0 µg)

14 JUN 2018

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.  
You are authorized to use this product for research use only. It is not intended for human use.

